Juno Therapeutics Inc. (JUNO) announced Wednesday morning that it has voluntarily placed its Phase II clinical trial of JCAR015, in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, on a clinical hold. The decision was made after two patients suffered cerebral edema earlier this week and died.
from RTT - Before the Bell http://ift.tt/2gGXyPY
via IFTTT
No comments:
Post a Comment